Danish diabetes giant Novo Nordisk (NOV:N) has pledged to limit its price rises for US patients.
Jakob Riis, president of Novo Nordisk Inc, has written an open letter on the company’s website in which he tackles the issue of pricing and affordability.
"We will limit any potential future list price increases for our medicines to no more than single-digit percentages annually"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze